Scarica l'app Stockscreener
1.60
5.26%
0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Immunic Inc Borsa (IMUX) Ultime notizie
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies - Proactive Investors UK
Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies - Proactive Investors USA
Immunic, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.22) Per Share (NASDAQ:IMUX) - Defense World
Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX), - Yahoo Finance
Research Analysts Offer Predictions for Immunic, Inc.'s Q3 2024 Earnings (NASDAQ:IMUX) - MarketBeat
Leerink Partnrs Upgrades Immunic (NASDAQ:IMUX) to Strong-Buy - Defense World
Immunic (NASDAQ:IMUX) Upgraded by Leerink Partnrs to "Strong-Buy" - MarketBeat
Immunic’s (IMUX) Outperform Rating Reaffirmed at Leerink Partners - Defense World
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com Australia
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com India
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com Canada
Immunic stock gets Outperform rating amid optimism for MS drug pipeline - Investing.com UK
Immunic, Inc. (NASDAQ:IMUX) Receives $12.75 Consensus Target Price from Analysts - MarketBeat
Immunic (NASDAQ:IMUX) Receives Outperform Rating from Leerink Partners - MarketBeat
Immunic drug targeting post-COVID syndrome in Phase 2 trialICYMI - Proactive financial news
Immunic Welcomes Jason Tardio As COO And President - Contract Pharma
Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors Australia
Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors USA
Immunic shares hold steady price target, overweight on MS program potential - Investing.com
Immunic shares hold steady price target, overweight on MS program potential - Investing.com India
Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial - Proactive Investors USA
EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - sharewise
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - PR Newswire
Immunic extends Executive Chairman's term, raises salary - Investing.com
Immunic extends Executive Chairman's term, raises salary By Investing.com - Investing.com Canada
Immunic extends Executive Chairman's term, raises salary By Investing.com - Investing.com UK
Immunic, Inc. (NASDAQ:IMUX) Short Interest Down 6.3% in August - MarketBeat
There is no doubt that Immunic Inc (IMUX) ticks all the boxes. - SETE News
Immunic Inc (IMUX) shows promising results - US Post News
Immunic, Inc. (NASDAQ:IMUX) Sees Large Decrease in Short Interest - Defense World
Immunic, Inc. (NASDAQ:IMUX) to Post Q3 2024 Earnings of ($0.23) Per Share, B. Riley Forecasts - MarketBeat
Immunic to highlight lead asset’s promise at upcoming Multiple Sclerosis R&D Day - Proactive Investors UK
Market Resilience: Immunic Inc (IMUX) Finishes Weak at 1.40, Down -3.10 - The Dwinnex
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September - StockTitan
Immunic initiated with a Buy at B. Riley - TipRanks
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September - Yahoo Finance
B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential - Investing.com
Immunic (NASDAQ:IMUX) Now Covered by B. Riley - Defense World
B. Riley Initiates Coverage on Immunic (NASDAQ:IMUX) - MarketBeat
B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential - Investing.com India
Immunic Inc (IMUX) Stock: A Year of Market Fluctuations - The InvestChronicle
Immunic Stock (NASDAQ:IMUX): CEO Says “Right Time to Buy Now” - TipRanks
Immunic, Inc. (NASDAQ:IMUX) Short Interest Down 8.8% in July - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Shares Purchased by Vanguard Group Inc. - MarketBeat
Vanguard Group Inc. Buys 1,703,047 Shares of Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic, Inc.'s (NASDAQ:IMUX) Shift From Loss To Profit - Simply Wall St
Biotech Alert: Searches spiking for these stocks today - TipRanks
Immunic (NASDAQ:IMUX) Rating Increased to Hold at StockNews.com - MarketBeat
StockNews.com Upgrades Immunic (NASDAQ:IMUX) to Hold - Defense World
Multiple Sclerosis Pipeline Drugs 2024 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, Ge - Barchart
Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript - Seeking Alpha
Immunic: Q2 Earnings Snapshot - San Antonio Express-News
Immunic Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Immunic: Q2 Earnings Snapshot - San Francisco Chronicle
Immunic CEO discusses Q2 results & MS trials update - Proactive Investors USA
Immunic: Q2 Earnings Snapshot - CTPost
Immunic strengthens leadership team as MS trials advance toward key milestones - Proactive Investors UK
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Immunic: Q2 Earnings Snapshot - Barchart
Immunic (IMUX) Set to Announce Earnings on Thursday - Defense World
Here’s Why Immunic’s IMU-856 Program for Celiac Disease Looks Promising - TipRanks
Janus Henderson Group PLC Acquires New Holdings in Immunic, Inc. (NASDAQ:IMUX) - MarketBeat
Immunic (IMUX) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at StockNews.com - Defense World
Immunic (NASDAQ:IMUX) Upgraded by StockNews.com to "Hold" - MarketBeat
IMUXImmunic, Inc. Latest Stock News & Market Updates - StockTitan
1.26%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):